11th Sep 2015 11:29
THOUSAND OAKS (Alliance News) - British drug maker AstraZeneca PLC on Friday announced that it purchased a high-tech biologics bulk manufacturing facility in the US from Amgen Inc to support its growing pipeline. The financial details were not disclosed. This investment does not impact AstraZeneca's financial guidance for 2015.
The Boulder, Colorado-based LakeCentre facility will increase manufacturing and production capacity of AstraZeneca to support the company's extensive portfolio of biologics medicines. The facility will eventually double the biologics manufacturing capacity in the US to meet the needs of the maturing AstraZeneca pipeline.
AstraZeneca plans to start staffing the facility immediately to support refurbishment and infrastructure improvements. Once complete, the site is expected to be operational and licensed for commercial production by late 2017.
In the longer- term, this facility could create up to 400 highly skilled jobs, subject to relevant approvals by the local authorities.
The has already announced in May a planned biologics manufacturing investment in Sweden, and the expansion in Frederick, Maryland, announced in November 2014.
Copyright RTT News/dpa-AFX
Related Shares:
Astrazeneca